findmyKOL
Clinical trialNCT01369121TerminatedPhase 1/PHASE2Interventional

Tolerability Study of Xerecept® in Pediatric Patients

SponsorCeltic Pharma Development ServicesEnrollment15Brain EdemaBrain Tumor
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Stewart Goldman, MD

    Ann & Robert H Lurie Children's Hospital of Chicago

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Children'S Memorial Hospital, Northwestern University Feinberg School of Medicine

    Chicago, Illinois, United States

  • Dana-Farber Cancer Institute Pediatric Oncology

    Boston, Massachusetts, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Jun 2010
Primary completion
31 Oct 2012
Completion
31 Mar 2013
Last update posted
30 Jul 2013
Registered enrollment
15
Registry id
NCT01369121

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.